The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Other GLP-1 agonists, including Zepbound ...

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking semaglutide ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...